| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2001;32:669.)
© 2001 American Heart Association, Inc.
Original Contributions |
Have Randomized Controlled Trials of Neuroprotective Drugs Been Underpowered?
An Illustration of Three Statistical Principles
From the Center for Clinical Health Policy Research (G.P.S., D.B.M.) and Departments of Medicine (G.P.S., D.B.M.) and Community and Family Medicine (G.P.S.), Duke University Medical Center, Durham, NC; and Department of Veterans Affairs Hospital (D.B.M.), Durham, NC.
Correspondence to Gregory P. Samsa, PhD, Duke University Medical Center, Suite 230, First Union Building, 2200 W Main St, Durham, NC 27705. E-mail samsa001{at}mc.duke.edu
Background and Purpose—The results of phase III trials of neuroprotective drugs for acute ischemic stroke have been disappointing. We examine the question of whether these trials may have been underpowered.
Methods—Computer simulations were based on the binomial distribution.
Results—We illustrate that even small overestimates of the efficacy of an intervention can lead to a serious reduction in statistical power, that the use of data from phase II studies tends to lead to such overestimation, and that a minimum clinically important difference derived with cost-effectiveness modeling techniques is considerably smaller than might be suggested by intuition.
Conclusions—We recommend placing more emphasis on minimum clinically important differences when planning stroke trials, with these differences being derived from an assessment of the public health impact obtained in conjunction with the use of epidemiological and cost-effectiveness models. Even small benefits, when averaged over a sufficiently large number of cases, will, in total, accrue to a large positive impact on the public health.
Key Words: clinical trials • epidemiology • models, statistical • sample size • stroke, ischemic
This article has been cited by other articles:
 |
|
 |
|
  K. B. Slot, E. Berge, P. Dorman, S. Lewis, M. Dennis, P. Sandercock, and on behalf of the Oxfordshire Community Stroke Proj Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies BMJ, February 16, 2008; 336(7640): 376 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fisher and for the Stroke Therapy Academic Industry Roundtabl Enhancing the Development and Approval of Acute Stroke Therapies: Stroke Therapy Academic Industry Roundtable Stroke, August 1, 2005; 36(8): 1808 - 1813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Matchar Editorial Comment--What Can Models Teach Us About Stroke Treatment?: Sorting Out the Missing Bits Stroke, June 1, 2004; 35(6): 1497 - 1498. [Full Text] [PDF]
|
|
|
|
|
|
M. Fisher Recommendations for Advancing Development of Acute Stroke Therapies: Stroke Therapy Academic Industry Roundtable 3 Stroke, June 1, 2003; 34(6): 1539 - 1546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Matchar Health Policy in Stroke: Translating What We Know Into What We Do Stroke, February 1, 2003; 34(2): 370 - 371. [Full Text] [PDF]
|
|
|
|
 |
|
 K W Muir Magnesium in stroke treatment Postgrad. Med. J., November 1, 2002; 78(925): 641 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Furlan Acute Stroke Trials: Strengthening the Underpowered Stroke, June 1, 2002; 33(6): 1450 - 1451. [Full Text] [PDF]
|
|
|
|
|
|
K. W. Muir Heterogeneity of Stroke Pathophysiology and Neuroprotective Clinical Trial Design Stroke, June 1, 2002; 33(6): 1545 - 1550. [Abstract] [Full Text] [PDF]
|
|